



OUR VISION
IS TO INCREASE
CANCER CURE
BY 30% BY 2030

inPROBE[®]
Smart Cancer Diagnostics

We create the Future of Fighting Cancer and give oncologists a novel disruptive technology to increase Patients' survival rate.

One core platform technology:
wide scale-up opportunities and applications.


One vision: Increase Cancer Cure Rate by min. 30% by 2030.



Co-funded by the Horizon 2020 programme
of the European Union



sdsptic.com



DISRUPTIVE PLATFORM TECHNOLOGY WITH GLOBAL POTENTIAL TO CHALLENGE THE PARADIGM OF IN-VITRO HISTOPATHOLOGY TESTING REAL-TIME TARGETED DRUGS DELIVERY MONITORING TOOL


Nowadays millions of people die each year because of cancer. It's a big challenge for medical professionals to save lives with limited molecular diagnostics options available. At the same time the future of cancer therapies is here with several targeted, gene or immune-therapies being available globally. Their efficiency and success rates strictly depend on proper and quick targeted tumor biology diagnostics what does not exist today. Old-fashioned biopsy and histopathology techniques are being questioned and challenged

due to growing no. of false positives or false negatives results as well as shortage of pathologists globally. That's why we've invented and developed **inPROBE**. Platform technology connecting targeted therapies with targeted diagnostics. Technology merging photonics with molecular biology, immunochemistry and biomedical engineering in one multidisciplinary device. Technology capable of reducing diagnosis time, increasing precision and success rates of innovative personalized cancer treatments.

inPROBE®
Smart Cancer Diagnostics

TIME IS KEY IN CANCER DIAGNOSTICS

Meet the future of fighting cancer



PERSONALIZED TARGETED POINT-OF-CARE DIAGNOSTICS

HELPING ONCOLOGISTS TO IDENTIFY THE RIGHT PATIENTS WHO BENEFIT THE MOST FROM INNOVATIVE TARGETED TREATMENTS



PATIENTS WELLBEING

Less pain. No waiting time.
Immediate personalized targeted
treatment introduction lowering
high stress



IN VIVO EXAMINATION AND REAL TIME RESULTS

No tissue biopsy
Results in minutes



HIGH SENSITIVITY

No tumor infraction benefiting
with no CANCER METASTASIS.
Enough to get close to the
tumor with USG guidance



NUMEROUS SCALE-UP POSSIBILITIES

Most cancer biomarkers
Real-time drug delivery in SITU
monitoring
Surgical oncology
Infectious diseases
and many others



OBJECTIVE RESULTS

Numerical results
No more false results

Increase cancer cure rate by 30%

Our vision is to develop innovative cancer diagnostics & monitoring technologies which will help increase cancer survival by 30% by 2030. We will achieve that with implementing real-time, in vivo and numerical based molecular diagnostics & monitoring technologies.



9 mln

people will die
this year
because of
cancer



70%

the increase in new
cases of cancer
expected over the
next 2 decades
(27 mln people in 2040)



Breast Cancer

2,3 mln new Breast
Cancer cases in 2020
globally

685 000 deaths

**Real-Time / In Vivo / No False +/- targeted tumor
molecular biology diagnostics in KEY**



Standard Biopsy
& Histopathology Testing

**results often in weeks
visual examination
often false +/- results
Pathologists' shortage**





InPROBE

**on-site PoC testing
results in minutes
numerical based results
no false results**


www.inprobe.com

DISRUPTIVE TECHNOLOGY WITH WIDE SCALE-UP OPPORTUNITIES





HOW IT WORKS?




- Disruptive 6-micron opto-biological Platform Technology
- Merging molecular biology with novel photonics technologies, chemistry and biomedical engineering in a single needle
- In essence putting the biology diagnostics tests at the tip of the fiber optic Microprobe
- Single-cell resolution Microprobe HER2 tumor biomarker in breast cancers as first in-human clinical application (clinical trials ongoing)
- Shorten tumor markers testing from several days or weeks to several minutes, without painful tissue biopsy and laboratory waiting-time

**HELPING ONCOLOGISTS TO
IDENTIFY THE RIGHT
PATIENTS WHO BENEFIT
THE MOST FROM
INNOVATIVE TARGETED
TREATMENTS**


**inPROBE CAN
INCREASE CANCER
CURE RATE
BY 30% BY 2030**

www.inprobe.com

HOW IT WORKS?



TESTIMONIALS



— SDS-MicroProbe can be a groundbreaking solution to overcome problems in current technology and enable analysis of biological processes inside the single cell in their natural state. As an expert in hematology, I am convinced that such solution would find several applications in research as well as in future cell therapies in the cancer area.

**Hematologist/Oncologist M.D. PhD
with several years of scientific experience at NIH
Bethesda, MD, USA**

— There is an unmet need to study biological processes within individual cells residing in their native niche. The SDS-MicroProbe addresses this shortcoming; it is a new approach in analyzing key intracellular parameters that indicate the functionality of a cell. The SDS-MicroProbe has the potential to substantially advance our ability

to assess the status of living cells and thereby improve our ability to diagnose various diseases and evaluate the efficacy of interventions.

**Prof. PhD of Harvard Medical School
Boston, MA, USA**

— The InProbe has the potential to swiftly replace traditional IHC and FISH examinations, should this be confirmed by correlation studies of the probe results and quantitative analysis of HER2 expression. Further applications will appear very soon, together with newly introduced targeted drugs in clinical practice. There are several dozens of them today.

**Prof. PhD. D.D.
European Society of Surgical Oncology (ESSO)
Board Member
Lublin, Poland**

www.inprobe.com



ABOUT US



SDS Optic Inc. is an Europe-based cutting-edge Health Tech company, which connects vast **molecular biology with novel photonics technologies, chemistry & biomedical engineering** to create solutions that can revolutionize healthcare worldwide.

Our multidisciplinary Team consists of renown **scientists, engineers and business experts** bounded with one vision.

We discover, develop and commercialize disruptive diagnostics and monitoring tools on a global scale. We strive to create lifesaving innovations which can **help medical professionals in real-time diagnosis and monitoring** as well as increase Patients' well-being.

We are a MedTech-Bio Powerhouse building strong and long-term R&D pipeline with Academia and early-stage startups to **move Lifesaving Photonics Innovations from Science to the Market.**



OUR VISION IS TO INCREASE CANCER CURE RATE BY **30% BY 2030**

THE BEGINNING 2013-2016

SDS Optic develops 6-micron optical fiber microprobe – the base for the future inPROBE technology

Positive testimonials and LoI from **Key Opinion Leaders** in the U.S. and Europe

Pre-clinical in-vitro testing on human cancer cells (HER2-positive breast cancers)

€3mln funding from early stage investors and non-dilutive grants

2017-2018

PCT patents applications with a global IP protection

Phase 1 Pre-clinical animal testing (mouse models)

European Commission SME Instrument **Horizon2020 €4mln** non-dilutive funding

€1mln VC funding

R&D Center in Lublin, Poland kick-off, growing to almost 700m2 and 40 scientists as of end 2021

2019

Phase 2 Pre-clinical animal testing (rat models) with human HER2 overexpressing breast cancer cell lines

SDS Optic LLC becomes **SDS Optic Inc.**

First technology scale-up in vitro studies (drug delivery monitoring)

Preparatory phase for **clinical studies** and **regulatory approvals**

2020


€2,5mln non-dilutive grant funding secured for scaling up of the core inPROBE technology – infectious diseases (incl. SARS-CoV-2)

Pilot production of 2700pcs inPROBE microprobes and detecting devices in the lab environment

Introducing **new long-term strategy** focusing on R&D, inPROBE platform technology scale-up and M&A of Lifesaving Innovations

www.inprobe.com

GLOBAL PRESENCE



2021

Phase 3 Pre-clinical animal testing confirmed absolute safety

Kicking off clinical trials on 220 patients targeting HER2-positive breast cancers

€2,5mln Pre-IPO Series A funding

SARS-CoV-2 high-volume in-vitro photonics biosensors application R&D kick-off

Moving into new high-class 700m2 R&D Laboratory Center (Lublin, Poland)

2022

Going public at the Warsaw Stock Exchange (NewConnect market)

Long-term enterprise value building for the shareholders

Phase 1 Clinical Trials – safety study

Setting-up of inProbe microprobes pilot production line

Scientific Advisory Board Assembling

2023

Corporate Partnering & Technology Scale-up

Building R&D Center in the United States

Pilot production of inPROBE disposable probes in the semi-industrial clean-room environment

ISO13485 Certification

Phase 2 Clinical Trials – efficacy study

Clinical Trials wrap-up

2024-2026

EU-MDR and CE Mark Certification

FDA approval for reference HER2+ Breast Cancer Diagnostics application

Corporate Partnering & Technology Scale-up

US R&D Center development

FiBioMed technology certification


Market Go Live

inPROBE full scale clean room pilot production

Long-term enterprise value delivery for shareholders with potential secondary listing on the **US or West Europe stock exchange**

ESOP for key employees wrap-up

www.inprobe.com



OUR TEAM



Marcin Staniszewski,
MSc Eng.

Co-Founder, CEO & Senior Engineer

Experienced scientist and engineer with several years of experience in R&D engineering projects obtained at US companies, incl. NASA Laboratory and Glenn Research Center in Cleveland, OH. University of Akron (Akron, OH) graduate, founder of several technology startups in the United States.



Magdalena Staniszewska,
PhD, DSc.

Co-Founder / Chief Science Officer

Leading biotechnology scientist with several years of experience at Harvard Medical

School in Boston, MA (USA) and the Polish Academy of Sciences. A scientist with broad experience in discovering molecular bases of diseases, identifying targets and developing new therapeutic strategies for diabetic complications, cancer and eye diseases. Co-invented analytical tools and diagnostic markers of pathological neovessels, holds a track record of scientific publications and public speaking.



Mateusz Sagan, MBA


SVP / Chief Operating & Business Officer

Experienced Leader and Executive Manager, specialized in strategic management, sales management, biotech/medtech start-ups commercialization and business development. Several years as CEO and Board Executive at large international corporate businesses in the U.S., Switzerland and Eastern Europe, in BPO and consumer goods sectors. TEDx Speaker, MBA graduate from University of Central Lancashire Preston, UK


We are publicly listed company



www.inprobe.com



You can find information about us on our social media channels, in breaking news, tv programs and press releases.



-  facebook.com/sdsoptic
- facebook.com/inprobemedtech
-  instagram.com/sdsoptic
-  twitter.com/inPROBE_
- twitter.com/SDS_Optic
-  youtube.com/@SDSOptic
-  linkedin.com/company/sds-optic
-  inprobe.com
-  sdsoptic.com




Co-funded by the Horizon 2020 programme of the European Union

Awarded by:



www.inprobe.com



inPROBE[®]

Smart Cancer Diagnostics



inprobe.com



Co-funded by the Horizon 2020 programme
of the European Union



European
Commission



SDS Optic Inc.

ul. Głęboka 39,
20-612 Lublin
POLAND



@sdsoptic



@SDS_Optic



/company/sds-optic

mail: press@sdsoptic.com

www.sdsoptic.com

www.inprobe.com